The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
GBD 2023 Cancer Collaborators
https://pubmed.ncbi.nlm.nih.gov/41015051/Actively Recruiting
Led by Nanfang Hospital, Southern Medical University · Updated on 2026-06-03
500
Participants Needed
1
Research Sites
21 weeks
Total Duration
Researchers are investigating the key molecular factors that affect the prognosis of malignant tumors by combining detailed clinical information with advanced molecular data. This observational study aims to build precise models to predict outcomes, find potential treatment targets, and improve clinical care for adult patients who have received antitumor therapy at a single hospital between January 2017 and December 2025. The study collects clinical data such as patient demographics, tumor pathology, treatment history, and survival follow-up from electronic medical records. It also gathers tumor tissue or blood samples for various laboratory tests including sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry. These tests help characterize the genetic makeup, immune environment, and cell diversity of the tumors. Participants have received different treatments such as immunotherapy, radiotherapy, or surgery, sometimes combined with chemotherapy or targeted therapy. Participants will be involved through data collection from medical records and biological samples. Researchers will monitor overall survival for up to five years from treatment start, along with progression-free survival and responses after surgery following neoadjuvant therapy. This study includes follow-up assessments to understand clinical outcomes and tumor characteristics in detail, contributing to more personalized cancer care strategies.
CONDITIONS
Correlation Analysis of Gene Characteristics of Malignant Tumors With Prognosis
W
Wei Wang Wang
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Nanfang Hospital, Southern Medical University
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Varies by treatment modality and patient condition
Participants receive immunotherapy, radiotherapy, or undergo surgery as part of their treatment for malignant tumors.
Visit schedule depends on treatment type and clinical care
Duration - Typically 4 to 6 weeks after completion of neoadjuvant therapy
Participants who undergo surgery are followed up to assess pathological response and recovery.
1 to 2 visits depending on surgical and treatment course
Duration - Up to 5 years
Participants are monitored for overall and progression-free survival for up to 5 years following treatment initiation.
Periodic visits for follow-up assessments
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
GBD 2023 Cancer Collaborators
https://pubmed.ncbi.nlm.nih.gov/41015051/Ian A Prior, Paul D Lewis, Carla Mattos
https://pubmed.ncbi.nlm.nih.gov/22589270/Dung T Le, Jennifer N Durham, Kellie N Smith...
https://pubmed.ncbi.nlm.nih.gov/28596308/Caterina Marchiò, Laura Annaratone, Ana Marques...
https://pubmed.ncbi.nlm.nih.gov/32112814/Robert M Samstein, Chung-Han Lee, Alexander N Shoushtari...
https://pubmed.ncbi.nlm.nih.gov/30643254/Maria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner...
https://pubmed.ncbi.nlm.nih.gov/41151697/Tony S K Mok, Yi-Long Wu, Iveta Kudaba...
https://pubmed.ncbi.nlm.nih.gov/30955977/Patricia Cortazar, Lijun Zhang, Michael Untch...
https://pubmed.ncbi.nlm.nih.gov/24529560/Thomas J Lynch, Daphne W Bell, Raffaella Sordella...
https://pubmed.ncbi.nlm.nih.gov/15118073/Ramón Rami-Porta, Katherine K Nishimura, Dorothy J Giroux...
https://pubmed.ncbi.nlm.nih.gov/38447919/Nanfang Hospital, Southern Medical University
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Collaborating Sponsor